Date published: 2026-4-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

CDK2AP2 Inhibitors

CDK2AP2 inhibitors constitute a distinct class of chemical compounds that have attracted scientific attention due to their potential to modulate the activity of CDK2AP2, or cyclin-dependent kinase 2-associated protein 2. CDK2AP2 plays a role in cell cycle regulation and cellular proliferation, making it a noteworthy target for research into controlling fundamental cellular processes. These inhibitors encompass a diverse range of molecules, each possessing unique structural features and mechanisms of action that enable them to interfere with the functioning of CDK2AP2. Structurally, CDK2AP2 inhibitors exhibit varying chemical scaffolds, including small molecules and synthetic compounds, which allow them to interact with specific binding sites or functional domains within the CDK2AP2 protein. Mechanistically, these inhibitors exert their effects through different avenues. Some inhibitors may directly bind to CDK2AP2, disrupting its interactions with partner molecules and potentially altering its regulatory role in cell cycle progression. Others could affect CDK2AP2 indirectly by modulating pathways that influence its activity or gene expression. The study of CDK2AP2 inhibitors has contributed to a deeper understanding of the molecular mechanisms by which CDK2AP2 contributes to cellular processes. Researchers have explored the intricate three-dimensional structure of CDK2AP2, aiding the design and optimization of inhibitors that can selectively target specific regions of the protein. Additionally, these inhibitors have undergone rigorous biochemical and biophysical analyses to decipher their modes of interaction with CDK2AP2 and elucidate the precise mechanisms through which they hinder its function. The realm of CDK2AP2 inhibitors continues to evolve, with ongoing research shedding light on novel insights into their mechanisms of action and potential applications. As the intricate roles of CDK2AP2 in cellular processes are further unveiled, the development and refinement of inhibitors within this class hold promise for expanding our understanding of fundamental biological mechanisms.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

A-485

1889279-16-6sc-507493
5 mg
$275.00
(0)

A-485 is an inhibitor of bromodomain-containing proteins. Its effects on gene expression could indirectly influence CDK2AP2-related pathways by altering the epigenetic landscape.

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$231.00
$863.00
1
(0)

JQ1 is another bromodomain inhibitor that can disrupt gene transcription. Its action on gene expression could potentially intersect with CDK2AP2-mediated cellular processes.

SNS-032

345627-80-7sc-364621
sc-364621A
5 mg
10 mg
$169.00
$262.00
(1)

SNS-032 is a cyclin-dependent kinase inhibitor that primarily targets CDK2 and CDKIts impact on CDK2 activity might indirectly affect the regulatory role of CDK2AP2 in cell cycle progression.

PHA-793887

718630-59-2sc-364580
sc-364580A
5 mg
10 mg
$189.00
$432.00
(0)

PHA-793887 is a small molecule that inhibits several cyclin-dependent kinases, including CDKIts effects on CDK2 activity could have implications for CDK2AP2-regulated pathways.

Dinaciclib

779353-01-4sc-364483
sc-364483A
5 mg
25 mg
$247.00
$888.00
1
(0)

Dinaciclib is a potent CDK inhibitor with activity against multiple CDKs, including CDKIts effects on CDK2 activity might have downstream consequences for CDK2AP2-mediated processes.

P276-00

920113-03-7sc-477932
1 mg
$380.00
(0)

P276-00 is a cyclin-dependent kinase inhibitor that could potentially affect CDK2AP2-mediated pathways by targeting CDK2, a key player in the cell cycle.